The article A Deeper Look at atai Life Sciences’ Company Update was originally published on Microdose. atai Life Science has released its most recent...
I am optimistic that the market will perform better in 2023 and think the sell-off could be a great opportunity to invest in some of those...
The article Atai Announces Disappointing Results in PCN-101 Phase 2a Trial was originally published on Microdose. The industry has been waiting for these...
Atai plans to continue working with its compound despite the setback. The post Atai Life Sciences Ketamine Treatment for Depression Fails in Mid-Stage...
NEW YORK and BERLIN, Jan. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “the Company”), a clinical-stage biopharmaceutical...
The article Top 3 Psychedelic Storylines to Watch in 2023 was originally published on Microdose. 2022 was a milestone year for the psychedelic industry...
Some analysts have called the industry's business model problematic. The post Despite Psychedelic Industry Buzz, Some Have Crashed Already appeared first...
The article 2022 End of Year Review: atai Life Sciences was originally published on Microdose. The end of the year is a convenient time to look...
Also a peek at their plans for the year ahead. The post How 5 Psychedelics Companies Fared in 2022 appeared first on Green Market Report.
NEW YORK and BERLIN, Dec. 16, 2022 (GLOBE NEWSWIRE) -- atai Impact, the philanthropic arm of atai Life Sciences N.V. (NASDAQ: ATAI) (“atai”), today...